Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy

Epilepsy and Behavior

Volumn 4, Issue 6, 2003, Pages 659-666

  Kaminow, Leonard ^a   Schimschock, James R ^b   Hammer, Anne E ^c   Vuong, Alain ^c  

^a Maine Neurology   (United States)

^b GlaxoSmithKline ^*

^c GLAXOSMITHKLINE   (United States)

Author keywords

Carbamazepine; Epilepsy; Lamotrigine; Monotherapy; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; PHENYTOIN; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; ARTICLE; ASTHENIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HEADACHE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF EVALUATION; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TREMOR; UNITED STATES;

EID: 0347418145     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yebeh.2003.08.033     Document Type: Article

References (25)

1. Matsuo F. Lamotrigine. Epilepsia 1999;40(Suppl 5):S30-36.
2. Brodie MJ, Richens A, Yuen AWC, et al. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9.
3. Steiner TJ, Dellaportas CI, Findley LJ. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999;40:601-7.
4. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312-22.
5. Messenheimer JA, Mullens EL, Giorgi L, et al. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998;18:281-96.
6. Uvebrant P, Bauzien PR. Intractable epilepsy in children: the efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 1994;25:284-9.
7. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-7.
8. Commission on classification and terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1989;30:389-99.
9. Cramer JA, Perrine K, Devinsky O, et al. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia 1998;39:81-8.
10. Vickrey BG, Perrine KR, Hays RD, et al. Quality of life in epilepsy QOLIE-31 (version 1.0): score manual and patient inventory. Santa Monica, CA: Rand; 1993.
11. Loiseau P, Yuen AWC, Duche B, et al. A randomized double-blind crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990;7:136-45.
12. Reunanen M, Dam M, Yuen AWC. A randomized open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996;23:149-55.
13. Brodie MJ, Overstall PW, Giorgi L, et al. Multicentre, double-blind, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 1999;37:81-7.
14. Binnie CD, Debets MMC, Engelsman M, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 1989;4:222-9.
15. Jawad S, Richens A, Goodwin G, et al. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989;30:356-63.
16. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-91.
17. Messenheimer J, Ramsay RE, Wilmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, crossover trial. Epilepsia 1994;35:1113-21.
18. Sander JWAS, Patsalos PN, Oxley JR, et al. A randomized, double-blind, placebo-controlled, add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990;6:221-6.
19. Schapel GJ, Beran RG, Vajda FJE, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant partial seizures. J Neurol Neurosurg Psychiatry 1993;56:448-53.
20. Boas J, Dam M, Friis ML, et al. Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures. Acta Neurol Scand 1996;94:247-52.
21. Karceski S, Morrell M, Carpenter D. The Expert Consensus Guideline Series: treatment of epilepsy. Epilepsy Behav 2001;2:A1-50.
22. Living with epilepsy: report of a Roper poll of patients on quality of life. Roper Organization; 1992.
23. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996;49:769-73.
24. Messenheimer JA. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci 1998;25:S14-8.
25. LAMICTAL (lamotrigine) Tablets Prescribing Information. GlaxoSmithKline; June 2003.